+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)


Heparin Market - Growth, Trends, and Forecast (2020 - 2025)

  • ID: 4896104
  • Report
  • January 2020
  • Region: Global
  • 115 pages
  • Mordor Intelligence
until Jun 30th 2020
1 of 4

Enquire about COVID-19 updates for this product.

Enquire Now


  • Aspen Holding
  • B Braun Melsungen AG
  • Baxter
  • Bioiberica
  • Dr. Reddy's Laboratories
  • Leo Pharma
  • MORE
Market Overview

Heparin is a medication and naturally occurring glycosaminoglycan, which is used as an anticoagulant (blood thinner). Specifically, it is also used in the treatment of heart attacks and unstable angina. It is usually given by injection into a vein or under the skin or in oral for in some cases.

Recently, due to an increase in mortality and prevalence of chronic diseases like cardiovascular disorders. As heparin acts as an anticoagulant that prevents the formation of blood clots, it is used before surgery to reduce the risk of in the veins, arteries, or lungs. As a result, the demand for heparin has increased. Moreover, the geriatric population is more prone to such chronic diseases, and hence, increasing the geriatric population is also increasing the demand for these surgeries. These factors have helped the growth if the market.

However, side-effects of heparin are refraining the patients from its use. This is restraining market growth.

Scope of the Report

Heparin is used as an anticoagulation agent which allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed.

In the report, a detailed analysis of the heparin market is provided. The market is evaluated by collating revenues generated across segments, categorized by Product, Source Mode of Administration, Application, and Geography.

Key Market Trends

Parenteral administered medication is expected to dominate the market

While heparin does not break down clots that have already formed (unlike tissue plasminogen activator), it allows the body's natural clot lysis mechanisms to work normally to break down clots that have formed. Heparin is generally used for anticoagulation for the following conditions including Acute coronary syndrome, Atrial fibrillation, etc. These disorders are linked to several forms of cardiovascular disease like high blood pressure, coronary artery disease, hypertrophic cardiomyopathy (HCM), pericarditis, congenital heart disease, and previous heart surgery.

Moreover, cardiovascular disease is the leading global cause of death, accounting for more than 17.6 million deaths per year in 2016, a number that is expected to grow to more than 23.6 million by 2030, according to a 2014 study.

North America is Expected to Dominate the Market

According to the American Heart Association, cardiovascular disease (CVD), listed as the underlying cause of death, accounting for 840,678 deaths in the United States (US) in 2016, which is approximately 1 of every 3 deaths. In Mexico, CVD mortality is 292 per 100 000 population according to a 2015 OECD report. However, this rate is expected to increase in the future due to high obesity and diabetes rates. According to the Public Health Agency of Canada 2017 report, about 2.4 million, accounting for 8.5% of Canadian adults aged 20 years and older live with diagnosed ischemic heart disease, including 578,000 (2.1%) with a history of a heart attack. The high rate of CVD directly impacts the rate of surgeries for CVDs, which in turn positively impacts the heparin market.

Moreover, the United States (US) and Canada have a developed and well-structured health care system. These systems also encourage research and development. These policies encourage global players to enter the US and Canada. As a result, these countries enjoy the presence of many global market players. As high and increasing demand is met by the presence of global players in the region, the heparin market is further expected to increase.

Competitive Landscape

The majority of the heparin is being manufactured by the global key players. Market leaders with more funds for research and a better distribution system have established their position in the market. Moreover, Asia-pacific is witnessing the emergence of some small players due to the rise of awareness. This has also helped the market grow.

Reasons to Purchase this report:
  • The market estimate (ME) sheet in Excel format.
  • Report customization as per the client's requirements.
  • 3 months of analyst support.
Note: Product cover images may vary from those shown
2 of 4


  • Aspen Holding
  • B Braun Melsungen AG
  • Baxter
  • Bioiberica
  • Dr. Reddy's Laboratories
  • Leo Pharma
  • MORE
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Chronic Diseases
4.2.2 Rise in Geriatric Population
4.3 Market Restraints
4.3.1 Side Effects of Heparin
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Product
5.1.1 Unfractionated Heparin
5.1.2 Low Molecular Weight Heparin (LMWH)
5.1.3 Ultra-Low Molecular Weight Heparin (ULMWH)
5.2 By Source
5.2.1 Bovine
5.2.2 Porcine
5.3 By Mode of Administration
5.3.1 Oral
5.3.2 Parenteral
5.4 By Application
5.4.1 Atrial Fibrillation & Heart Attack
5.4.2 Stroke
5.4.3 Deep Vein Thrombosis (DVT)
5.4.4 Pulmonary Embolism (PE)
5.4.5 Others
5.5 Geography
5.5.1 North America United States Canada Mexico
5.5.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.5.3 Asia Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.5.4 Middle East and Africa GCC South Africa Rest of Middle East and Africa
5.5.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Aspen Holding
6.1.2 B Braun Melsungen AG
6.1.3 Baxter
6.1.4 Bioiberica
6.1.5 Dr. Reddy's Laboratories
6.1.6 Hebei Changshan Biochemical Pharmaceutical
6.1.7 Leo Pharma
6.1.8 Opocrin
6.1.9 Pfizer
6.1.10 Shenzhen Hepalink Pharmaceutical Group

Note: Product cover images may vary from those shown
3 of 4


4 of 4
  • Aspen Holding
  • B Braun Melsungen AG
  • Baxter
  • Bioiberica
  • Dr. Reddy's Laboratories
  • Hebei Changshan Biochemical Pharmaceutical
  • Leo Pharma
  • Opocrin
  • Pfizer
  • Shenzhen Hepalink Pharmaceutical Group
Note: Product cover images may vary from those shown